Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma). TLX591-CDx (Illuccix) for prostate cancer imaging China: An Investigational New Drug (IND) application has been submitted by Telix's partner in Greater China, Grand Pharma, to the National Medical Products...
Source: singaporestar.com